Erratum to: A ‘Global Reference’ Comparator for Biosimilar Development
نویسندگان
چکیده
منابع مشابه
A Reference Model for Global Software Development
The objective of this paper is to propose a reference model for global software development, based on the results found in a case study conducted in two software development units from multinational organizations located in Brazil. Since the number of organizations distributing their software development processes worldwide keeps increasing, this change is having a profound impact on the way pr...
متن کاملBiosimilar Development: the Race to Market Continues..
2012 will certainly be memorable as an Olympic year, but it has also seen a flurry of activity in the race to market biosimilar products. Keen to participate in this event, many countries throughout the world have established legal and regulatory pathways which allow manufacture of “copies” of a patent-expired biotherapeutic product. However, these are not simple generics as in the case of smal...
متن کاملa new approach to credibility premium for zero-inflated poisson models for panel data
هدف اصلی از این تحقیق به دست آوردن و مقایسه حق بیمه باورمندی در مدل های شمارشی گزارش نشده برای داده های طولی می باشد. در این تحقیق حق بیمه های پبش گویی بر اساس توابع ضرر مربع خطا و نمایی محاسبه شده و با هم مقایسه می شود. تمایل به گرفتن پاداش و جایزه یکی از دلایل مهم برای گزارش ندادن تصادفات می باشد و افراد برای استفاده از تخفیف اغلب از گزارش تصادفات با هزینه پائین خودداری می کنند، در این تحقیق ...
15 صفحه اولBiosimilar Development: from Science to Market
The biotechnology industry has established itself as a major source of new human therapeutic protein drugs which can be described as complex biological entities. The majority of these in production, such as erythropoeitin (EPO), interleukin-2 (IL-2), interferon (IFN), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF) and tissue plasminogen ...
متن کاملEstablishment of reference standards in biosimilar studies.
When an innovative biological product goes off-patent, biopharmaceutical or biotechnological companies may file an application for regulatory approval of biosimilar products. In practice, however, important information on the innovative (reference) product may not be available for assessment. Thus, it is important to first establish a reference standard while assessing biosimilarity between a b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BioDrugs
سال: 2017
ISSN: 1173-8804,1179-190X
DOI: 10.1007/s40259-017-0236-3